Association of Urinary Biomarkers of Inflammation, Injury, and Fibrosis with Renal Function Decline: The ACCORD Trial
Association of Urinary Biomarkers of Inflammation, Injury, and Fibrosis with Renal Function Decline: The ACCORD Trial
复制标题
DOI：
10.2215/cjn.12051115
复制
发表时间：
2016-08-01
影响因子：
9.8
通讯作者：
Coca, Steven G.
中科院分区：
文献类型：
--
作者：
Nadkarni, Girish N.;Rao, Veena;Coca, Steven G.
背景和目的目前预测2型糖尿病患者肾功能下降的方法并不令人满意，多个指标评估各种生物轴可能会提高预测。我们研究了四种生物标志物与肌酐比值水平之间的关系，（单核细胞趋化蛋白-1，IL-18，肾损伤分子-1，YKL-40）与肾脏预后的关系。设计，设置，参与者，我们在控制心血管疾病的行动试验中使用了嵌套病例对照设计，将190名参与者与5年随访期间eGFR持续下降>= 40%的参与者相匹配。最多190名参与者
Background and objectives Current measures for predicting renal functional decline in patients with type 2 diabetes with preserved renal function are unsatisfactory, and multiple markers assessing various biologic axes may improve prediction. We examined the association of four biomarker-to-creatinine ratio levels (monocyte chemotactic protein-1, IL-18, kidney injury molecule-1, and YKL-40) with renal outcome.Design, setting, participants, & measurements We used a nested case-control design in the Action to Control Cardiovascular Disease Trial by matching 190 participants with >= 40% sustained eGFR decline over the 5-year follow-up period to 190 participants with